›Publications›Development of 111-In-Labelled DOTA urotensin II analogues for targeting the UT receptor overexpressed in solid tumours. Development of 111-In-Labelled DOTA urotensin II analogues for targeting the UT receptor overexpressed in solid tumours. Auteurs : Poret B, Desrues L, Bonin MA, Pedard M, Dubois M, Leduc R, Modzelewski R, Decazes P, Morin F, Vera P, Castel H, Bohn P, Gandolfo P. Revue : Biomolecules Année : 2020 Groupe : QuantIF ← Retour aux publications